Mevion Launches Proton Therapy Platform for Existing Radiotherapy Departments
Mevion Medical Systems presented its MEVION S250-FIT Proton Therapy System to the European radiation oncology community during ESTRO 2026. According to the company, the platform is the first proton therapy system designed for installation within a standard radiation therapy vault, allowing cancer centers to integrate proton therapy into existing radiotherapy departments.
The system is both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745. Mevion stated that the S250-FIT platform was developed to align with existing radiotherapy infrastructure, workflows, and capital planning strategies commonly used in LINAC-based treatment environments.
Designed for Existing Clinical Infrastructure
The company noted that the S250-FIT system supports installation within conventional radiotherapy vaults without requiring construction of a dedicated proton therapy building.
On April 7, 2026, Stanford Medicine unveiled the first installation of the S250-FIT platform, developed in collaboration with Leo Cancer Care. According to Mevion, the system was installed within a standard 110 m² (1,200 sq ft) LINAC vault at the Stanford Medicine Cancer Center in Palo Alto, California.
The platform combines Mevion’s proton therapy technology with Leo Cancer Care’s Marie Upright Patient Positioning and CT Imaging System.
According to the companies, the upright positioning system includes integrated diagnostic CT imaging and is intended to support:
- Upright patient treatment positioning
- Organ motion management
- Advanced image-guided workflows
- Adaptive treatment approaches
Advanced Proton Therapy Features
The S250-FIT system delivers intensity-modulated proton therapy using Mevion’s HYPERSCAN pencil beam scanning technology and Adaptive Aperture proton multi-leaf collimator.
The company stated that the platform is also designed to support:
- DirectARC proton arc therapy
- Adaptive radiotherapy workflows
- Image-guided proton therapy
- FLASH radiotherapy research applications
Mevion noted that the platform was developed to support integration into existing oncology departments while maintaining compatibility with modern radiation oncology workflows.
Global Installations and Expansion Plans
The company presented the platform during ESTRO 2026 as part of its expansion into European proton therapy markets.
“With FIT™, proton therapy is no longer limited by infrastructure. For the first time, it can be deployed within the same clinical and operational framework as conventional radiotherapy,” said Tina Yu, Ph.D., CEO and President of Mevion Medical Systems. “For European health systems that have long recognized the benefits of proton therapy but faced significant infrastructure and financial barriers, this changes the question from whether to build a separate proton facility to how to integrate proton therapy into the radiotherapy programs they already operate,” Yu added.
Source: Mevion Medical Systems
